| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b62052129b3c4d7febfe7990b116ddc0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f1c06d6cdb6de344a71728db8cf02e2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1676
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate |
2006-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef0dee0a470b9204072770e69c322c0a |
| publicationDate |
2006-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006082089-A1 |
| titleOfInvention |
Oral dosage form comprising rosiglitazone |
| abstract |
An oral dosage form comprising pellets of a first composition and pellets of a second composition, each composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier therefor, wherein the first and second compositions are arranged to release drug at differing release rates on administration, preferably such that the rate of release of the drug from the dosage form is substantially independent of pH; a process for preparing such a dosage form and the use of such a dosage form in medicine. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008074097-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9241910-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2476418-A1 |
| priorityDate |
2005-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |